Cargando…

Optimal Dosing and Patient Selection for Electrochemotherapy in Solid Abdominal Organ and Bone Tumors

The primary aim of this study was to analyze studies that use electrochemotherapy (ECT) in “deep-seated” tumors in solid organs (liver, kidney, bone metastasis, pancreas, and abdomen) and understand the similarities between patient selection, oncologic selection, and use of new procedures and techno...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Cora H., Martin, Robert C. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451240/
https://www.ncbi.nlm.nih.gov/pubmed/37627860
http://dx.doi.org/10.3390/bioengineering10080975
_version_ 1785095389928488960
author Martin, Cora H.
Martin, Robert C. G.
author_facet Martin, Cora H.
Martin, Robert C. G.
author_sort Martin, Cora H.
collection PubMed
description The primary aim of this study was to analyze studies that use electrochemotherapy (ECT) in “deep-seated” tumors in solid organs (liver, kidney, bone metastasis, pancreas, and abdomen) and understand the similarities between patient selection, oncologic selection, and use of new procedures and technology across the organ systems to assess response rates. A literature search was conducted using the term “Electrochemotherapy” in the title field using publications from 2017 to 2023. After factoring in inclusion and exclusion criteria, 29 studies were analyzed and graded based on quality in full. The authors determined key patient and oncologic selection characteristics and ECT technology employed across organ systems that yielded overall responses, complete responses, and partial responses of the treated tumor. It was determined that key selection factors included: the ability to be administered bleomycin, life expectancy greater than three months, unrespectability of the lesion being treated, and a later stage, more advanced cancer. Regarding oncologic selection, all patient cohorts had received chemotherapy or surgery previously but had disease recurrence, making ECT the only option for further treatment. Lastly, in terms of the use of technology, the authors found that studies with better response rates used the ClinporatorTM and updated procedural guidelines by SOP. Thus, by considering patient, oncologic, and technology selection, ECT can be further improved in treating lesions in solid organs.
format Online
Article
Text
id pubmed-10451240
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104512402023-08-26 Optimal Dosing and Patient Selection for Electrochemotherapy in Solid Abdominal Organ and Bone Tumors Martin, Cora H. Martin, Robert C. G. Bioengineering (Basel) Review The primary aim of this study was to analyze studies that use electrochemotherapy (ECT) in “deep-seated” tumors in solid organs (liver, kidney, bone metastasis, pancreas, and abdomen) and understand the similarities between patient selection, oncologic selection, and use of new procedures and technology across the organ systems to assess response rates. A literature search was conducted using the term “Electrochemotherapy” in the title field using publications from 2017 to 2023. After factoring in inclusion and exclusion criteria, 29 studies were analyzed and graded based on quality in full. The authors determined key patient and oncologic selection characteristics and ECT technology employed across organ systems that yielded overall responses, complete responses, and partial responses of the treated tumor. It was determined that key selection factors included: the ability to be administered bleomycin, life expectancy greater than three months, unrespectability of the lesion being treated, and a later stage, more advanced cancer. Regarding oncologic selection, all patient cohorts had received chemotherapy or surgery previously but had disease recurrence, making ECT the only option for further treatment. Lastly, in terms of the use of technology, the authors found that studies with better response rates used the ClinporatorTM and updated procedural guidelines by SOP. Thus, by considering patient, oncologic, and technology selection, ECT can be further improved in treating lesions in solid organs. MDPI 2023-08-18 /pmc/articles/PMC10451240/ /pubmed/37627860 http://dx.doi.org/10.3390/bioengineering10080975 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Martin, Cora H.
Martin, Robert C. G.
Optimal Dosing and Patient Selection for Electrochemotherapy in Solid Abdominal Organ and Bone Tumors
title Optimal Dosing and Patient Selection for Electrochemotherapy in Solid Abdominal Organ and Bone Tumors
title_full Optimal Dosing and Patient Selection for Electrochemotherapy in Solid Abdominal Organ and Bone Tumors
title_fullStr Optimal Dosing and Patient Selection for Electrochemotherapy in Solid Abdominal Organ and Bone Tumors
title_full_unstemmed Optimal Dosing and Patient Selection for Electrochemotherapy in Solid Abdominal Organ and Bone Tumors
title_short Optimal Dosing and Patient Selection for Electrochemotherapy in Solid Abdominal Organ and Bone Tumors
title_sort optimal dosing and patient selection for electrochemotherapy in solid abdominal organ and bone tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451240/
https://www.ncbi.nlm.nih.gov/pubmed/37627860
http://dx.doi.org/10.3390/bioengineering10080975
work_keys_str_mv AT martincorah optimaldosingandpatientselectionforelectrochemotherapyinsolidabdominalorganandbonetumors
AT martinrobertcg optimaldosingandpatientselectionforelectrochemotherapyinsolidabdominalorganandbonetumors